@article{8f41d7c91cf74b6c98a39bb9294db47a,
title = "In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis",
author = "Yeh, {Han I.} and Hwang, {Tzyh Chang}",
note = "Funding Information: Conflict of interest: H-I. Yeh has been supported by a research grant (#109-2320-B-010-049-MY2) from the Ministry of Science and Technology, Taiwan, to T-C. Hwang, who is also supported partly by the Cystic Fibrosis Foundation (Hwang19G0). T-C. Hwang is serving as a consultant for Nanova Inc.; through the University of Missouri, he has a service agreement with AbbVie Inc. Funding Information: Support statement: This work was supported by Cystic Fibrosis Foundation Therapeutics (grant: Hwang19G0) and the Ministry of Science and Technology, Taiwan (grant: 109-2320-B-010-049-MY2). Funding information for this article has been deposited with the Crossref Funder Registry.",
year = "2022",
month = feb,
day = "1",
doi = "10.1183/13993003.02380-2021",
language = "English",
volume = "59",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",
}